Copy to clipboard 
Meotec will supply bioresorbable magnesium alloy raw materials for Bioretec’s new RemeOs family of screw implants for trauma applications.
RemeOs implants are resorbed and replaced by bone, eliminating the need for removal surgery while supporting fracture repair. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets. U.S. and EU market authorization for the first RemeOs product is expected in 2022.
“Our teams at Meotec and Bioretec have worked together for several years to develop and supply an industry-leading biocompatible magnesium alloy which meets high requirements set for the materials. We are pleased that Bioretec has formalized the relationship with us as the future raw material supplier for the RemeOs products. With this supply agreement, Meotec expands its clientele with one of the markets most dynamic players in innovative orthopedic solutions,” said Alexander Kopp, CEO of Meotec.
Source: Bioretec
